Notably, treatment with either of these two inhibitors in combination with fulvestrant has shown to prolong progression-free survival against fulvestrant alone in patients with ER/PR positive and HER2 negative advanced breast cancer harboring PIK3CA- or AKT1-mutated or PTEN loss. Here, ESR1 is linked to breast carcinoma.